ATE265209T1 - Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten - Google Patents

Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten

Info

Publication number
ATE265209T1
ATE265209T1 AT97934005T AT97934005T ATE265209T1 AT E265209 T1 ATE265209 T1 AT E265209T1 AT 97934005 T AT97934005 T AT 97934005T AT 97934005 T AT97934005 T AT 97934005T AT E265209 T1 ATE265209 T1 AT E265209T1
Authority
AT
Austria
Prior art keywords
altering
circadic
peptid
neurokinin
rhythm
Prior art date
Application number
AT97934005T
Other languages
English (en)
Inventor
Carl M Mendel
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21806880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE265209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE265209T1 publication Critical patent/ATE265209T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97934005T 1996-07-17 1997-07-14 Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten ATE265209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2192496P 1996-07-17 1996-07-17
PCT/US1997/010931 WO1998002158A1 (en) 1996-07-17 1997-07-14 Alteration of circadian rhythmicity with a tachykinin antagonist

Publications (1)

Publication Number Publication Date
ATE265209T1 true ATE265209T1 (de) 2004-05-15

Family

ID=21806880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934005T ATE265209T1 (de) 1996-07-17 1997-07-14 Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten

Country Status (8)

Country Link
US (4) US6274604B1 (de)
EP (1) EP0912174B1 (de)
JP (1) JP2000514455A (de)
AT (1) ATE265209T1 (de)
AU (1) AU3716997A (de)
CA (1) CA2260269A1 (de)
DE (1) DE69728883T2 (de)
WO (1) WO1998002158A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912174B1 (de) * 1996-07-17 2004-04-28 MERCK & CO., INC. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US6271230B1 (en) * 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US7101547B1 (en) * 1999-01-22 2006-09-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
WO2001010355A1 (en) 1999-08-06 2001-02-15 Cook Biotech Incorporated Tubular graft construct
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
DE10001785A1 (de) * 2000-01-18 2001-07-19 Boehringer Ingelheim Pharma NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
JP4498140B2 (ja) 2002-08-30 2010-07-07 協和発酵キリン株式会社 行動障害治療剤
US7070568B1 (en) 2004-03-02 2006-07-04 Pacesetter, Inc. System and method for diagnosing and tracking congestive heart failure based on the periodicity of Cheyne-Stokes Respiration using an implantable medical device
US7094207B1 (en) 2004-03-02 2006-08-22 Pacesetter, Inc. System and method for diagnosing and tracking congestive heart failure based on the periodicity of cheyne-stokes respiration using an implantable medical device
US7179229B1 (en) 2004-04-07 2007-02-20 Pacesetter, Inc. System and method for apnea detection using blood pressure detected via an implantable medical system
US7371220B1 (en) 2004-06-30 2008-05-13 Pacesetter, Inc. System and method for real-time apnea/hypopnea detection using an implantable medical system
AR049655A1 (es) 2004-07-01 2006-08-23 Schering Corp Antagonistas de nk1
US8262578B1 (en) 2004-11-24 2012-09-11 Pacesetter, Inc. System and method for detecting physiologic states based on intracardiac electrogram signals while distinguishing cardiac rhythm types
US7361146B1 (en) 2004-11-24 2008-04-22 Pacesetter, Inc. System and method for detecting abnormal respiration via respiratory parameters derived from intracardiac electrogram signals
US7435221B1 (en) 2004-11-24 2008-10-14 Pacesetter, Inc. System and method for detecting abnormal respiration based on intracardiac electrogram signals using a pattern recognition device
US7354922B2 (en) * 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
US7538799B2 (en) * 2005-01-14 2009-05-26 Freescale Semiconductor, Inc. System and method for flicker detection in digital imaging
US7404799B1 (en) 2005-04-05 2008-07-29 Pacesetter, Inc. System and method for detection of respiration patterns via integration of intracardiac electrogram signals
US7628757B1 (en) 2005-05-25 2009-12-08 Pacesetter, Inc. System and method for impedance-based detection of pulmonary edema and reduced respiration using an implantable medical system
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0808030D0 (en) 2008-05-01 2008-06-11 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
WO2011019911A1 (en) 2009-08-14 2011-02-17 Opko Health, Inc. Intravenous formulations of neurokinin-1 antagonists
US8844537B1 (en) 2010-10-13 2014-09-30 Michael T. Abramson System and method for alleviating sleep apnea
US20150246140A1 (en) * 2014-02-10 2015-09-03 California Institute Of Technology Compositions and methods for modulating sleep and wakefulness
MX2017002988A (es) * 2014-09-09 2018-02-01 Torvec Inc Métodos y aparato para monitorear el nivel de alerta de una persona que utiliza un dispositivo portátil, y proporcionar una notificación.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991012266A1 (fr) 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Compose peptidique
DE69220258T2 (de) * 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
US5292726A (en) 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
EP0533280B2 (de) * 1991-09-20 2004-12-01 Glaxo Group Limited Neue medizinische Indikation für Tachykinin-Antagonisten
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2106330A1 (en) 1992-10-07 1994-04-08 Patrice J. Siret Antibiotic compounds
NZ277839A (en) 1993-12-29 1998-01-26 Merck Sharp & Dohme Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
GB9426103D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
US5531244A (en) * 1995-07-25 1996-07-02 Conval, Inc. Hemispherical ball valve
AU1977497A (en) * 1996-03-01 1997-09-16 Eli Lilly And Company Methods of treating or preventing sleep apnea
BR9709915A (pt) * 1996-06-21 1999-08-10 Merck Sharp & Dohme Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
GB9613969D0 (en) * 1996-07-03 1996-09-04 Merck Sharp & Dohme Therapeutic agents
EP0912174B1 (de) * 1996-07-17 2004-04-28 MERCK & CO., INC. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
PT1107744E (pt) 1998-08-25 2003-08-29 Wolfgang Mueller Utilizacao de antagonistas da substancia p para o tratamento do sindrome de fadiga cronica e/ou fibromialgia

Also Published As

Publication number Publication date
US6034105A (en) 2000-03-07
WO1998002158A1 (en) 1998-01-22
EP0912174A4 (de) 2000-12-06
US6525073B2 (en) 2003-02-25
CA2260269A1 (en) 1998-01-22
EP0912174A1 (de) 1999-05-06
JP2000514455A (ja) 2000-10-31
EP0912174B1 (de) 2004-04-28
DE69728883T2 (de) 2005-04-07
US20020035059A1 (en) 2002-03-21
DE69728883D1 (de) 2004-06-03
US6329401B1 (en) 2001-12-11
US6274604B1 (en) 2001-08-14
AU3716997A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
ATE265209T1 (de) Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
MY131298A (en) 5-heteroyl indole derivatives
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
DE69726414D1 (de) Antagonisten der endothelinwirkung
EP1280531A4 (de) Methoden zur lokalanästhesie und kit
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
MX9700030A (es) Administracion de pirenzipina, matilescopolamina y otros antagonistas del receptor mascurinico para el tratamiento de transtornos del metabolismo de lipidos.
GR3015087T3 (en) (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol.
NO963064D0 (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
NZ334063A (en) use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses
BG105932A (en) Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
NZ266559A (en) Peptide antagonists of cellular glutamate or NMDA receptors
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
WO2004002463A3 (en) Method of promoting smoking cessation
ATE247639T1 (de) Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
DE60019162D1 (de) Zolmitriptanhaltige arzneizusammensetzungen
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DK0923550T3 (da) Acylaminoalkylen-amid-derivater som NK1- og NK2-antagonister
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE69330272D1 (de) 4-imidomethyl-1-[2'-phenyl-2-oxoethyl]-piperidine als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung
ITMI940039A0 (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
NZ513851A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
ATE269072T1 (de) Synergistische kombination von nk1-rezeptor antagonisten und gaba analogen
ATE449078T1 (de) 5-ht7 rezeptor-antagonisten
YU39392A (sh) Sastav smeše aktivnih jedinjenja inhibitora karbonske anhidraze i beta-adrenergičnog antagonista

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties